LIT publication named “Highlight of Biomedical Research” in July by the Medical Faculty of the University of Regensburg
A publication on the hidden potential of the gene LMO4 to enhance the cancer-fighting abilities of T cells has been selected as the “Highlight of Biomedical Research” in July by the Medical Faculty of the University of Regensburg. The study authored by LIT researchers Dr. Dr. Roland Schelker, head of the Clinical Translation Group “T-Cell Fitness” at the LIT and specialist in hematology/oncology at the University Hospital Regensburg, and Prof. Luca Gattinoni, Head of LIT Research Division “Functional Immune Cell Modulation”, was published in the high-impact journal Signal Transduction and Targeted Therapy.
Article Details
-
Date Published
July 1, 2025
The research demonstrates that the protein LMO4 specifically promotes the maintenance of “stem cell-like” memory T cells, which are critical for the success of T-cell therapies. LMO4 enhances T-cell expansion, memory formation, polyfunctionality and anti-tumor efficiency, acting through the IL21/STAT3 signaling pathway.
About “Highlights of Biomedical Research” of the Medical Faculty of the University of Regensburg:
The “Highlight of Biomedical Research” platform offers researchers the opportunity to showcase outstanding research achievements, providing valuable insights into the Faculty’s contributions. All selected highlights are automatically considered for the Medical Faculty’s publication award.
Explore all “Highlights of Biomedical Research” here:
https://www.uni-regensburg.de/medizin/fakultaet/forschung/glanzlichter-biomedizinischer-forschung/index.html
Dr. Dr. Roland Schelker (left) and Prof. Luca Gattinoni (right)
For more information, please visit the full article in the journal “Signal Transduction and Targeted Therapy”:
Roland C. Schelker, Jessica Fioravanti, Fabio Mastrogiovanni, Jeremy G. Baldwin, Nisha Rana, Peng Li, Ping Chen, Timea Vadász, Rosanne Spolski, Christoph Heuser-Loy, Dragana Slavkovic-Lukic, Pedro Noronha, Giuseppe Damiano, Laura Raccosta, Daniela Maggioni, Sree Pullugula, Jian-Xin Lin, Jangsuk Oh, Patrick Grandinetti, Mario Lecce, Leo Hesse, Emilia Kocks, Azucena Martín-Santos, Claudia Gebhard, William G. Telford, Yun Ji, Nicholas P. Restifo, Vincenzo Russo, Michael Rehli, Wolfgang Herr, Warren J. Leonard, Luca Gattinoni. LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling. Signal Transduct Target Ther, 2024.
Explore our Translation Group in greater depth!
Get to know our team and find out more about our pioneering research.
Explore our Research Division in greater depth!
Get to know our team and find out more about our pioneering research.